Study of Epratuzumab in Systemic Lupus Erythematosus
Public ClinicalTrials.gov record NCT00382837. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III Multi-Center, OpenLabel, Follow-Up Study to Assess the Safety & Efficacy of Epratuzumab in Patients With Acute Severe SLE Flares Excluding the Renal or Neurologic Systems
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Epratuzumab is an investigational antibody designed to help treat SLE. The purpose is to evaluate safety and long term efficacy in concert with standard SLE treatments
Study identification
- NCT ID
- NCT00382837
- Recruitment status
- Withdrawn
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- Not listed
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 2007 (Type not available)
- Primary completion
- Not listed
- Completion
- Not listed
- Last update posted
- May 21, 2014
Started 2007
United States locations
- U.S. sites
- 20
- U.S. states
- 16
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | — | — |
| Not listed | Tucson | Arizona | — | — |
| Not listed | Los Angeles | California | — | — |
| Not listed | Upland | California | — | — |
| Not listed | Farmington | Connecticut | — | — |
| Not listed | Washington D.C. | District of Columbia | — | — |
| Not listed | Aventura | Florida | — | — |
| Not listed | Chicago | Illinois | — | — |
| Not listed | Baltimore | Maryland | — | — |
| Not listed | New York | New York | — | — |
| Not listed | Syracuse | New York | — | — |
| Not listed | The Bronx | New York | — | — |
| Not listed | Durham | North Carolina | — | — |
| Not listed | Winston-Salem | North Carolina | — | — |
| Not listed | Gallipolis | Ohio | — | — |
| Not listed | Tulsa | Oklahoma | — | — |
| Not listed | Charleston | South Carolina | — | — |
| Not listed | Dallas | Texas | — | — |
| Not listed | Arlington | Virginia | — | — |
| Not listed | Edmonds | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 34 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00382837, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 21, 2014 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00382837 live on ClinicalTrials.gov.